Moxivar

Moxifloxacin

Treatment of adult ≥18 yr w/ bacterial infections eg, acute exacerbations of chronic bronchitis, community acquired pneumonia, acute bacterial sinusitis, complicated skin & skin structure infections; complicated intra-abdominal infections.

Adult ≥18 yr Recommended dose: 400 mg IV over 1 hr once daily. Duration of treatment: Acute exacerbations of chronic bronchitis 5-10 days. Community-acquired pneumonia 10 days. Acute sinusitis 7 days. Complicated skin & skin structure infections 7-21 days (sequential IV/oral). Complicated intra-abdominal infections 5-14 days (sequential IV/oral therapy). Mild to moderate pelvic inflammatory disease 14 days.

Hypersensitivity to moxifloxacin or other quinolones. History of tendon disease or disorder related to quinolone treatment. Congenital or acquired QT prolongation, electrolyte disturbances, bradycardia, heart failure w/ reduced left-ventricular ejection fraction, history of symptomatic arrhythmias. Pregnancy & lactation. Patient <18 yr.

Hypersensitivity & allergic reactions may occur after 1st administration. Discontinue treatment if anaphylactic reactions progress to a life threatening shock. May increase risk of tendinitis & tendon rupture in elderly >60 yr; in patients concomitantly taking corticosteroids; w/ renal, heart or lung transplant. Discontinue treatment at first sign of pain or inflammation. Concomitant use w/ medication that reduce K & Mg level. May increase the risk for ventricular arrhythmias including Torsades de pointes. Discontinue treatment & perform ECG if signs of cardiac arrhythmia occur during treatment. Patients w/ CNS disorders which may predispose to seizures or lower the seizure threshold; myasthenia gravis. Bullous skin reactions eg, SJS or TEN; pseudomembranous colitis. Consult a physician immediately prior to continuing treatment if skin &/or mucosal reactions & symptoms related to liver failure occur. Patients who develop serious diarrhea during or after treatment. Patients w/ G6PD deficiency. Patients for whom Na intake is of medical concern. Avoid exposure to either UV irradiation or extensive sunlight during treatment. Consult an eye specialist in case of vision disorders. Not recommended in patients w/ complicated pelvic inflammatory disease for whom an IV treatment is necessary. Fulminant hepatitis leading to liver failure. Not recommended in patients w/ severe hepatic impairment (Child Pugh C). Perform LFTs. Pregnancy & lactation. Elderly, women.

Mycotic superinfections; headache, dizziness; QT prolongation in patients w/ hypokalaemia; nausea, vomiting, GI & abdominal pain, diarrhea; increased transaminases; inj & infusion site reactions.

Should be administered at least 4 hr before or 8 hr after antacids containing Al or Mg, didanosine, sucralfate & agents containing Fe or Zn. Concomitant use of drugs that induce bradycardia, hypokalemia or QT prolongation including neuroleptic, anti-infectives (eg, antimalarials, azole antimycotics, macrolides), antihistaminic (eg, terfenadine, astemizole), cisapride. Antiarrhythmic drugs class IA (eg, quinidine & procainamide) & III (eg, amiodarone & sotalol). Increased anticoagulant activity w/ concurrent use of anticoagulants. Reduced systemic availability w/ charcoal.

Quinolones

J01MA14 - moxifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.

G